Αρχική World News FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq... World News FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Από Ogkologos - 12 Αυγούστου, 2026 183 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Precision-T study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR The HPV Vaccine: Increasing the Use of an Important Cancer Prevention... 20 Δεκεμβρίου, 2018 Professional Runner and Mom of Two Shares Photo Of Belly Cavity... 17 Σεπτεμβρίου, 2019 Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True 27 Σεπτεμβρίου, 2021 Study Finds Light Therapy Helps Radiation-Related Skin Damage Heal 50% Faster 3 Φεβρουαρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event... New study to detect oesophageal cancer earlier